Navigation Links
BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
Date:2/16/2012

RALEIGH, N.C. and CHADDS FORD, Pa., Feb. 16, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance of BDSI's patent application (No. 13/184306) that, once formally granted, will extend the exclusivity of the BioErodible MucoAdhesive (BEMA) drug delivery technology for BEMA Buprenorphine and BEMA Buprenorphine/Naloxone from 2020 to 2027. 

A Notice of Allowance is issued when the USPTO has determined to grant a patent.  Once the issue fee is paid, the final granting of the patent takes place, typically within a few months.

As a part of BDSI's recently signed BEMA Buprenorphine licensing and development agreement with Endo Pharmaceuticals (Nasdaq: ENDP), BDSI is entitled to a milestone payment in the amount of $15 million upon the final granting of this patent. 

"We are very pleased by the allowance of this patent application by the USPTO, that will not only provide non-dilutive capital to BDSI in the next couple months, but importantly extends the period of exclusivity, and thus the potential for a longer royalty stream, for BEMA Buprenorphine in its use for treating chronic pain following FDA approval and commercial launch," stated Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  "It is an added benefit that this patent upon granting will afford similar protection to BEMA Buprenorphine/Naloxone for the treatment of opioid dependence."

"Endo is committed to serving as an integrated solutions provider for the development and commercialization of products focused on the management of pain," said Dr. Ivan Gergel, M.D., executive vice president, R&D and chief scientific officer, Endo Pharmaceuticals. "And the allowance of t
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
2. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
3. BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector
4. Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
8. Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region
9. Excel Life Sciences Joins DATATRAKs Connect Partner Program
10. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
11. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" or ... contract R&D services provider, today announced that its board ... dated April 29, 2015, from a consortium (the "Consortium") ... founder, chairman and chief executive officer of the Company, ... a transaction (the "Transaction") involving the acquisition of all ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Clinovo ... 2015 PharmaSUG Annual Conference held in Orlando, FL ... Staffing Solutions along with Leslie Kolman, Manager of Staffing ... latest Clinovo news at Booth #17. , “We ... Conference again this year”, Says Trisha Heredia, Senior Director ...
(Date:4/29/2015)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced its results ... fiscal 2014 year-end financial statements and MD&A have been filed on SEDAR ... , 2014 , 2013 Revenue 3,968 , ... 1,326 , 1,703 , 2,231 , ... 3,377 , 4,562 Ebitda* 92 , 418 ...
(Date:4/29/2015)... (PRWEB) April 29, 2015 The leading ... announce that its regenerative stem cell therapy has processed ... 2002, seeking to discover a successful treatment for horses ... In 2003 VetStem signed a worldwide exclusive license for ... and the first horse was treated in January 2004. ...
Breaking Biology Technology:WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2
... CALGARY, Oct. 26 /PRNewswire-FirstCall/ - SemBioSys Genetics ... of therapeutic,proteins for metabolic and cardiovascular diseases, ... scientific poster and abstract at the Seventh ... by the Diabetes,Technology Society. The poster will ...
... ECG services, RESEARCH TRIANGLE PARK, N.C., Oct. ... H. Cabell, M.D., MHS,FACC, an expert cardiologist and ... group in Global Clinical Development Services,(CDS). In addition ... for Quintiles ECG Services. Cabell comes to ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) management will be presenting at ... Rodman & Renshaw 9th Annual Healthcare Conference being ... Hotel in New York City. Schaefer ... will provide an overview of the company on Tuesday, ...
Cached Biology Technology:SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting 2Expert Cardiologist Joins Quintiles Medical Group 2Pharmasset to Present at Three Investor Conferences in November 2007 2
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... of the most recent, popular supplements for athletes looking to ... acid called L-arginine. The reason for its popularity ... physiology. "First, L-arginine is a precursor for nitric oxide ... may aid the delivery of important nutrients to working muscles ...
... published this month in the Journal of the American ... Science Center at San Antonio have pinpointed the cancer-fighting potential ... Susan Mooberry, Ph.D., leader of the Experimental Development Therapeutics Program ... of pharmacology at the UT Health Science Center, has been ...
... Researchers at King,s College London have discovered how one ... pave the way for less harmful pain relief medications to ... in the US and Asia as acetaminophen, is a widely-used ... as cold and flu remedies. Although discovered in the ...
Cached Biology News:L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3Bat plant could give some cancers a devil of a time 2First study to reveal how paracetamol works could lead to less harmful pain relief medicines 2First study to reveal how paracetamol works could lead to less harmful pain relief medicines 3
... kit is a competitive enzymeimmunoassay (EIA) for ... or rat serum or plasma. Corticosterone is ... rats and mice, and in most non-mammalian ... Most mammals produce both corticosterone and cortisol, ...
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
7G10 anti-Fasciclin III...
Biology Products: